Rakhi  Kumar net worth and biography

Rakhi Kumar Biography and Net Worth

Rakhi Kumar serves as Chief Accounting Officer of Roivant Sciences. Ms. Kumar joined Roivant in September 2015, and previously served as Vice President, Finance and External Reporting. Prior to joining Roivant, Ms. Kumar was responsible for external reporting, corporate and technical accounting at The Medicines Company from 2013 to 2015. Earlier in her career, Ms. Kumar was in the assurance services at Ernst and Young.

Ms. Kumar also serves as a director and as chair of the audit committee for NeuroPace (NASDAQ: NPCE), a medical device company dedicated to reducing debilitating seizures in patients with epilepsy. She is a licensed Certified Public Accountant and a Chartered Professional Accountant in Ontario, Canada. She received her M.S. in Accounting and Taxation from the University of Hartford.

What is Rakhi Kumar's net worth?

The estimated net worth of Rakhi Kumar is at least $1.95 million as of September 8th, 2023. Ms. Kumar owns 197,950 shares of Roivant Sciences stock worth more than $1,945,849 as of December 10th. This net worth approximation does not reflect any other investments that Ms. Kumar may own. Learn More about Rakhi Kumar's net worth.

How old is Rakhi Kumar?

Ms. Kumar is currently 43 years old. There are 5 older executives and no younger executives at Roivant Sciences. The oldest executive at Roivant Sciences is Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management, who is 55 years old. Learn More on Rakhi Kumar's age.

How do I contact Rakhi Kumar?

The corporate mailing address for Ms. Kumar and other Roivant Sciences executives is Clarendon House, 2 Church Street, Hamilton Parish HM 11. Roivant Sciences can also be reached via phone at 44-20-7400-3347. Learn More on Rakhi Kumar's contact information.

Has Rakhi Kumar been buying or selling shares of Roivant Sciences?

Rakhi Kumar has not been actively trading shares of Roivant Sciences in the last ninety days. Most recently, Rakhi Kumar sold 99,350 shares of the business's stock in a transaction on Friday, September 8th. The shares were sold at an average price of $12.18, for a transaction totalling $1,210,083.00. Following the completion of the sale, the chief accounting officer now directly owns 197,950 shares of the company's stock, valued at $2,411,031. Learn More on Rakhi Kumar's trading history.

Who are Roivant Sciences' active insiders?

Roivant Sciences' insider roster includes Rakhi Kumar (CAO), and Eric Venker (COO). Learn More on Roivant Sciences' active insiders.

Are insiders buying or selling shares of Roivant Sciences?

In the last year, Roivant Sciences insiders bought shares 1 times. They purchased a total of 1,526,316 shares worth more than $58,000,008.00. In the last year, insiders at the sold shares 37 times. They sold a total of 48,678,289 shares worth more than $491,923,435.01. The most recent insider tranaction occured on October, 5th when COO Eric Venker sold 153,027 shares worth more than $1,547,102.97. Insiders at Roivant Sciences own 4.6% of the company. Learn More about insider trades at Roivant Sciences.

Information on this page was last updated on 10/5/2023.

Rakhi Kumar Insider Trading History at Roivant Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/8/2023Sell99,350$12.18$1,210,083.00197,950View SEC Filing Icon  
9/5/2023Sell1,724$12.00$20,688.00197,950View SEC Filing Icon  
8/3/2023Sell3,681$12.00$44,172.00199,328View SEC Filing Icon  
8/1/2023Sell336$12.00$4,032.00199,328View SEC Filing Icon  
7/18/2023Sell100$12.00$1,200.0082,128View SEC Filing Icon  
7/14/2023Sell535$12.00$6,420.0082,128View SEC Filing Icon  
6/9/2023Sell43,893$9.93$435,857.49198,582View SEC Filing Icon  
5/2/2023Sell15,517$8.42$130,653.14200,139View SEC Filing Icon  
4/28/2023Sell71,989$8.47$609,746.83200,139View SEC Filing Icon  
4/26/2023Sell87,830$8.68$762,364.40200,139View SEC Filing Icon  
10/25/2022Sell1,588$4.40$6,987.20139,354View SEC Filing Icon  
9/23/2022Sell1,741$3.07$5,344.87140,942View SEC Filing Icon  
8/24/2022Sell1,652$3.71$6,128.92142,683View SEC Filing Icon  
7/25/2022Sell1,686$4.33$7,300.38144,335View SEC Filing Icon  
6/23/2022Sell1,635$4.34$7,095.90146,021View SEC Filing Icon  
5/20/2022Sell12,127$3.70$44,869.90147,656View SEC Filing Icon  
4/25/2022Sell703$3.84$2,699.52159,783View SEC Filing Icon  
3/30/2022Sell2,486$4.84$12,032.24View SEC Filing Icon  
3/25/2022Sell7,281$5.06$36,841.86View SEC Filing Icon  
3/18/2022Sell2,153$5.13$11,044.89View SEC Filing Icon  
3/7/2022Sell3,091$5.52$17,062.32View SEC Filing Icon  
See Full Table

Rakhi Kumar Buying and Selling Activity at Roivant Sciences

This chart shows Rakhi Kumar's buying and selling at Roivant Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Roivant Sciences Company Overview

Roivant Sciences logo
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Read More

Today's Range

Now: $9.83
Low: $9.48
High: $9.84

50 Day Range

MA: $9.42
Low: $8.38
High: $10.80

2 Week Range

Now: $9.83
Low: $6.43
High: $13.24


4,957,546 shs

Average Volume

4,578,962 shs

Market Capitalization

$7.90 billion

P/E Ratio


Dividend Yield